Nur Ink: The Warrants and Shareholder Support, How Much Time Does the Financing Bridge Really Buy

The main article focused on whether commercialization is finally starting to work. This follow-up isolates the financing layer, because that is where the real bottleneck sits right now: not whether the company has one more product idea, but whether it has enough time before revenue begins to carry more of the load.

Four points need to be on the table immediately:

• At report date the company had only about NIS 1.6 million of cash, with no bank borrowings and no credit lines.
• The committed 10/24 exercises are expected to bring in about NIS 3.18 million, but that is cash pulled forward from warrants that were already in the money, not a new financing channel.
• The Series 1 extension attempt does not add cash today. It preserves future optionality at a time when the warrants were out of the money and none had been exercised.
• The layer that actually pushes the company above the 12-month line is the up-to-NIS 4.5 million commitment from the controlling shareholder and two additional shareholders. Without that layer, the bridge is much shorter.

What The Bridge Is Really Made Of

The starting point is sharp. At the end of 2025 the company had NIS 3.856 million of cash and cash equivalents, but by report date that had already fallen to about NIS 1.6 million. At the same time, the company explicitly said it had no bank or non-bank borrowings and no credit facilities. In other words, the financing bridge is not built on a bank balance sheet. It is built almost entirely on the capital market and on shareholders.

To estimate how much time that bridge really buys, it helps to use a simple all-in cash flexibility reference. In 2025 the company used NIS 7.528 million in operating cash flow and another NIS 130 thousand in investing cash flow. Together that is about NIS 7.66 million of cash use for the year, roughly NIS 638 thousand per month. This is not a 2026 forecast. It is a conservative reference line based on what the company actually did.

That is the heart of the story. Even if the full NIS 3.18 million from committed 10/24 exercises comes in, the company still does not reach a full year of funding on the 2025 burn reference. To get past the 12-month threshold, it effectively needs the shareholder support as well, or a much faster revenue ramp, or both.

10/24: Cash Pulled Forward, Not A New Solution

On February 24, 2026 the board asked shareholders to approve a temporary reduction in the exercise price of up to 1,637,940 10/24 warrants, which had been issued in August 2025 as part of a private placement to 14 offerees. The exercise price would fall from 800 agorot to 744 agorot, a 7% discount, but only for holders willing to submit an irrevocable commitment by February 25 at 17:00 to exercise immediately after shareholder approval.

The most important point is that this move was not made on paper that was far from exercise. The meeting notice said that the share price near the board decision stood at 1,248 agorot. In other words, the warrants were already deep in the money even before the temporary discount. This was not the creation of a new funding source. It was a relatively small price paid to accelerate cash that might otherwise have arrived later.

But here too, the actual result matters more than the headline. By the deadline the company had received commitments to exercise only 427,040 warrants from 8 holders, for total expected proceeds of about NIS 3.18 million. That is meaningful cash, but it represents only a limited part of the 1.64 million eligible warrants. In other words, even after offering a discount on an instrument that was already economically attractive, the company succeeded in pulling forward only part of the possible cash, not all of it.

The analytical implication is two-sided. On one hand, the company did prove it can generate liquidity from the existing capital structure without immediately launching another outright equity issue. On the other hand, this is one-time acceleration cash, not a repeatable financing engine. Once it comes in, it is no longer available for the next round.

Series 1: Future Optionality, Not Spring 2026 Cash

If 10/24 is the immediate-cash layer, Series 1 is almost the opposite. On March 5, 2026 the board decided to pursue an extension of the exercise period for 454,720 listed Series 1 warrants to May 26, 2027 instead of a May 2026 expiry. The company even went to court to obtain approval to convene both a shareholder meeting and a warrant-holder meeting under Section 350 of the Companies Law.

The reason is unusually clear in the court filing. As of March 4, 2026 the share price stood at about NIS 10.73, versus a NIS 14 exercise price. None of the warrants had been exercised. In addition, average share turnover in February 2026 was only about NIS 290 thousand. So the company was not asking to extend an instrument with cash already sitting behind it. It was trying to preserve an instrument that was out of the money and sitting in a fairly thin market.

That point is critical to understanding the bridge. Extending Series 1 may preserve upside optionality, but it does not solve the liquidity gap of spring 2026. For it to become real cash, the share price first has to rise above NIS 14, or at least move close enough to make the warrants relevant again. Until then, it is an option on future improvement, not a financing layer that belongs in the base case.

That also highlights the difference between the two warrant layers. 10/24 buys time by accelerating exercise of paper that was already economical. Series 1 tries to buy time by delaying expiry of paper that still is not. The first can produce cash if approvals are obtained. The second produces only possibility.

Shareholder Support: The Layer That Carries The 12-Month Assumption

The decisive part of the bridge actually came from shareholders. In March 2026 the company received a commitment from the controlling shareholder and two additional shareholders to provide up to NIS 4.5 million for current needs, upon the company’s request. That is the document that changes the liquidity read more than anything else in the package.

The reason is simple. The company states explicitly that its cash balance as of December 31, 2025 and at report date is not enough for more than 12 months, and that management intends to raise capital while also expecting additional 2026 revenues that are not certain to materialize. After that come the two bridge layers: committed 10/24 exercises and shareholder support. Only after both does management and the board say the company has sufficient sources for at least 12 months from approval of the accounts.

But this support is not free capital. If the money comes in as equity, the price will be the lower of the three-month average closing price before the funding date and the closing price on the funding date itself. If the share is weak, the support mechanism is therefore tilted toward dilution. If the money comes in as a loan, it bears interest at prime + 6% per year, and the supporting shareholders undertook not to demand repayment before June 30, 2027. In plain terms, the company gets time, but the price of that time is either dilution or expensive insider financing.

That also explains why there is no going-concern note. Not because the operating business already funds the company, but because another bridge has been placed above the operating business. That is an important distinction. The distance between “no going-concern note” and “self-funded economics” is still large.

So How Much Time Does The Bridge Really Buy

The short answer is that the bridge buys time, but not clean time. On the 2025 cash-burn reference, the cash at report date on its own is worth only about two to three months of activity. Even after adding the full NIS 3.18 million of committed 10/24 exercises, the company still gets only to roughly seven to eight months. Only if the shareholder backstop of up to NIS 4.5 million is genuinely available does the picture move past a year.

That is why any reading that stops at the headline “the warrants buy time” misses the point. 10/24 does buy time, but only first-layer time. Series 1 does not buy time today at all; it preserves a future possibility. And a full year is not being bought by the market. It is being bought mainly by shareholders.

That leads directly to the next test. If DTF, DCC, and the other commercial channels begin to push revenue up materially during 2026, this bridge may be enough for a reasonable transition year. If not, the company could find itself facing the same structure again: limited cash, a limited ability to pull warrants forward, and another layer of shareholder financing. That is the point at which a financing bridge stops looking temporary and starts looking like the business model.